# SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

> **NCT07021794** · PHASE2 · RECRUITING · sponsor: **Nancy Klimas** · enrollment: 100 (estimated)

## Conditions studied

- Post-COVID / Long-COVID

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** Sipavibart

## Key facts

- **NCT ID:** NCT07021794
- **Lead sponsor:** Nancy Klimas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07021794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07021794, "SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07021794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*